#Winningstrategy #Strategywellplayed Everyone is talking about the GLP-1 race, but the latest data from Boehringer tells a different story
Amino Acids
Look for a provider with experience in obesity medicine who offers comprehensive care not just a prescription
Disclosures: Janet Johnston: Nothing to Disclose, Youssef Barbour: Nothing to Disclose, Lisa Townshend-Bulson: Gilead Sciences: Grant/Research Support, Kena Desai: Nothing to Disclose, Chriss Homan: Nothing to Disclose, Wileina Rhodes: Nothing to Disclose, Brian McMahon: Nothing to Disclose 749 QUANTITATIVE ANALYSIS AND INTEGRATION OF MACHINE LEARNING FOR BIOMARKER ASSESSMENTS AND THEIR ASSOCIATION WITH TREATMENT RESPONSE: INSIGHTS FROM THE ENLIVEN PHASE 2B TRIAL OF PEGOZAFERMIN Oliver Mansbach 1 Arun Sanyal 2 Rada Savic 3 Leo Tseng 1 Kemal Balic 1 Shibao Feng 1 Lillian Tsai 1 Mildred Gottwald 1 Maya Margalit 1 Germaine Agollah 1 Hank Mansbach 1 Quentin Anstee 4 , 1 89bio, 2 Virginia Commonwealth University, 3 UCSF School of Pharmacy, 4 Newcastle University, UK Background: Pegozafermin (PGZ) is a long-acting glycoPEGylated analog of fibroblast growth factor 21 (FGF21)
After PSM, stain users and non-users (42,227 each) were well-matched
